Influence of adrenomedullin 2/intermedin gene polymorphism on blood pressure, renal function and silent cerebrovascular lesions in Japanese: The Ohasama study

Hypertension Research

Volumn 34, Issue 12, 2011, Pages 1327-1332

  Hirose, Takuo ^a   Totsune, Kazuhito ^a,b   Nakashige, Yukiko ^a   Metoki, Hirohito ^c   Kikuya, Masahiro ^a   Ohkubo, Takayoshi ^a,d   Hara, Azusa ^e   Satoh, Michihiro ^a   Inoue, Ryusuke ^c   Asayama, Kei ^a   Kondo, Takeo ^c   Kamide, Kei ^f   Katsuya, Tomohiro ^f   Ogihara, Toshio ^g   Izumi, Shin Ichi ^c   Rakugi, Hiromi ^f   Takahashi, Kazuhiro ^c   Imai, Yutaka ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU FUKUSHI UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e NATIONAL CANCER CENTER   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

adrenomedullin 2 intermedin; chronic kidney disease; polymorphism; silent cerebrovascular lesions

Indexed keywords

ADRENOMEDULLIN; INTERMEDIN;

ADULT; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEINURIA;

ADULT; AGED; ALLELES; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; CONFIDENCE INTERVALS; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDE HORMONES; POLYMORPHISM, GENETIC; PROTEINURIA; REAL-TIME POLYMERASE CHAIN REACTION; RISK; RNA, MESSENGER; RURAL POPULATION; YOUNG ADULT;

EID: 82955201843     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.131     Document Type: Article

References (47)

1. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54: 233-246. (Pubitemid 34575714)
2. Takei Y, Hyodo S, Katafuchi T, Minamino N. Novel fish-derived adrenomedullin in mammals: structure and possible function. Peptides 2004; 25: 1643-1656. (Pubitemid 39346206)
3. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett 2004; 556: 53-58. (Pubitemid 38058554)
4. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin generelated peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004; 279: 7264-7274. (Pubitemid 38248876)
5. Bell D, McDermott BJ. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol 2008; 153(Suppl 1): S247-S262. (Pubitemid 351340982)
6. Fujisawa Y, Nagai Y, Miyatake A, Takei Y, Miura K, Shoukouji T, Nishiyama A, Kimura S, Abe Y. Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. Eur J Pharmacol 2004; 497: 75-80. (Pubitemid 39099215)
7. Pan CS, Yang JH, Cai DY, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF. Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides 2005; 26: 1640-1646. (Pubitemid 41169759)
8. Ishimitsu T, Hosoya K, Tsukada K, Minami J, Futoh Y, Ono H, Ohrui M, Hino J, Kangawa K, Matsuoka H. Microsatellite DNA polymorphism of human adrenomedullin gene in normotensive subjects and patients with essential hypertension. Hypertension 2001; 38: 9-12. (Pubitemid 34224763)
9. Ishimitsu T, Tsukada K, Minami J, Ono H, Ohrui M, Hino J, Kangawa K, Matsuoka H. Microsatellite DNA polymorphism of human adrenomedullin gene in type 2 diabetic patients with renal failure. Kidney Int 2003; 63: 2230-2235. (Pubitemid 36605836)
10. Li Y, Staessen JA, Li LH, Gao PJ, Thijs L, Brand E, Brand-Herrmann SM, Zhu DL, Wang JG. Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population. Kidney Int 2006; 69: 1153-1158.
11. Imai Y, Nagai K, Sakuma M, Sakuma H, Nakatsuka H, Satoh H, Minami N, Munakata M, Hashimoto J, Yamagishi T, Yabe T, Nishiyama A, Abe K. Ambulatory blood pressure of adults in Ohasama, Japan. Hypertension 1993; 22: 900-912. (Pubitemid 23358099)
12. Imai Y, Satoh H, Nagai K, Sakuma M, Sakuma H, Minami N, Munakata M, Hashimoto J, Yamagishi T, Watanabe N, Yabe T, Nishiyama A, Nakatsuka H, Koyama H, Abe K. Characteristics of a community-based distribution of home blood pressure in Ohasama in northern Japan. J Hypertens 1993; 11: 1441-1449. (Pubitemid 24008493)
13. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sekino H, Nihei M, Yoshinaga K. Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. Am J Hypertens 1990; 3: 293-301. (Pubitemid 20215201)
14. Association for the Advancement of Medical Instrumentation. American National Standards for Electronic or Automated Sphygmomanometers. AAMI: Washington, DC. AAMI Analysis and Review. 1987.
15. White WB, Anwar YA. Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. Blood Press Monit 2001; 6: 107-110. (Pubitemid 32587668)
16. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-S20.
18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
20. Aono Y, Ohkubo T, Kikuya M, Hara A, Kondo T, Obara T, Metoki H, Inoue R, Asayama K, Shintani Y, Hashimoto J, Totsune K, Hoshi H, Satoh H, Izumi S, Imai Y. Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions: the Ohasama study. Arterioscler Thromb Vasc Biol 2007; 27: 963-968. (Pubitemid 46606732)
21. Hara A, Ohkubo T, Kondo T, Kikuya M, Aono Y, Hanawa S, Shioda K, Miyamoto S, Obara T, Metoki H, Inoue R, Asayama K, Hirose T, Totsune K, Hoshi H, Izumi S, Satoh H, Imai Y. Detection of silent cerebrovascular lesions in individuals with 'masked' and 'whitecoat' hypertension by home blood pressure measurement: the Ohasama study. J Hypertens 2009; 27: 1049-1055.
22. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43: 1683-1689. (Pubitemid 23307935)
23. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354: 2368-2374.
24. Morimoto R, Satoh F, Murakami O, Totsune K, Suzuki T, Sasano H, Ito S, Takahashi K. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides 2007; 28: 1095-1103. (Pubitemid 46654431)
25. Hirose T, Totsune K, Mori N, Mori T, Morimoto R, Metoki H, Asayama K, Kikuya M, Ohkubo T, Kohzuki M, Takahashi K, Imai Y. Expression of adrenomedullin 2/intermedin, a possible reno-protective peptide, is decreased in the kidneys of rats with hypertension or renal failure. Am J Physiol Renal Physiol 2010; 299: F128-F134.
26. Takahashi K, Kikuchi K, Maruyama Y, Urabe T, Nakajima K, Sasano H, Imai Y, Murakami O, Totsune K. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides 2006; 27: 1383-1389. (Pubitemid 43766993)
27. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539-546. (Pubitemid 29380290)
28. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36: 901-906.
29. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006; 47: 149-154. (Pubitemid 43189756)
30. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20: 2183-2189. (Pubitemid 35388236)
31. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406. (Pubitemid 36350739)
32. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
33. Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 2007; 22: 1910-1915. (Pubitemid 47244759)
34. Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, Ohashi Y, Ueshima H. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 2008; 118: 2694-2701.
35. Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 2009; 32: 115-121.
36. Hamid SA, Baxter GF. Adrenomedullin: regulator of systemic and cardiac homeostasis in acute myocardial infarction. Pharmacol Ther 2005; 105: 95-112.
37. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006; 111: 909-927. (Pubitemid 44118439)
38. Kato J, Tsuruda T, Kitamura K, Eto T. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 2003; 26(Suppl): S113-S119. (Pubitemid 36372326)
39. Fischer JA, Muff R, Born W. Functional relevance of G-protein-coupled- receptorassociated proteins, exemplified by receptor-activity-modifying proteins (RAMPs). Biochem Soc Trans 2002; 30: 455-460. (Pubitemid 35001576)
40. Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003; 285: H1506-H1514. (Pubitemid 37169504)
41. Hagiwara M, Bledsoe G, Yang ZR, Smith Jr RS, Chao L, Chao J. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol 2008; 295: F1735-F1743.
42. Jia YX, Yang JH, Pan CS, Geng B, Zhang J, Xiao Y, Zhao J, Gerns H, Yang J, Chang JK, Wen JK, Tang CS, Qi YF. Intermedin1-53 protects the heart against isoproterenolinduced ischemic injury in rats. Eur J Pharmacol 2006; 549: 117-123. (Pubitemid 44441261)
43. Ren YS, Yang JH, Zhang J, Pan CS, Yang J, Zhao J, Pang YZ, Tang CS, Qi YF. Intermedin 1-53 in central nervous system elevates arterial blood pressure in rats. Peptides 2006; 27: 74-79. (Pubitemid 43061039)
44. Yang JH, Jia YX, Pan CS, Zhao J, Ouyang M, Yang J, Chang JK, Tang CS, Qi YF. Effects of intermedin(1-53) on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem Biophys Res Commun 2005; 327: 713-719. (Pubitemid 40092808)
45. Yang JH, Cai Y, Duan XH, Ma CG, Wang X, Tang CS, Qi YF. Intermedin 1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II. Regul Pept 2009; 158: 19-25.
46. Taylor MM, Bagley SL, Samson WK. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. Am J Physiol Regul Integr Comp Physiol 2005; 288: R919-R927. (Pubitemid 40404167)
47. Taylor MM, Bagley SL, Samson WK. Intermedin/adrenomedullin-2 inhibits growth hormone release from cultured, primary anterior pituitary cells. Endocrinology 2006; 147: 859-864. (Pubitemid 43113003)